Please confirm you are human (Sign Up for free to never see this)
← Back to Search
The Future Of Immune Checkpoint Therapy
P. Sharma, J. Allison
Published 2015 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
This paper references
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Mutations of the BRAF gene in human cancer
Helen Davies (2002)
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Joseph F. Grosso (2013)
LAG-3 in Cancer Immunotherapy.
Monica V. Goldberg (2011)
VISTA Regulates the Development of Protective Antitumor Immunity.
I. Le Mercier (2014)
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
A. Amin (2014)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
D. Frederick (2013)
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
William L. Redmond (2013)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Signatures of mutational processes in human cancer
L. Alexandrov (2013)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
C. Robert (2014)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials
J. Madore (2015)
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F. S. Hodi (2014)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
H. Hammers (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
P. Sharma (2011)
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.
Nicolas J. Llosa (2015)
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
A. Hurwitz (1998)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo (2012)
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
Distinct sets of genetic alterations in melanoma.
J. A. Curtin (2005)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
O. Hamid (2013)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
A. V. D. van den Eertwegh (2012)
Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
P. Linsley (1992)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
The B7 family revisited.
R. Greenwald (2005)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
H. Dong (2002)
Cancer immunotherapy: moving beyond current vaccines
S. Rosenberg (2004)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
D. Ng Tang (2013)
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.
J. Fourcade (2012)
CTLA-4 can function as a negative regulator of T cell activation.
T. Walunas (1994)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
D. Le (2013)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi (2010)
A. are founders and advisors for Jounce Therapeutics
Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.
S. E. Townsend (1993)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis
J. Yang (2007)
CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
R. Waitz (2012)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
S. Ansell (2015)
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
C. E. Engeland (2014)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients
J. Fourcade (2010)
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
T. Fu (2011)
The TIM gene family: emerging roles in immunity and disease
Vijay K. Kuchroo (2003)
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
C. Liakou (2008)
Targeting CD137 enhances the efficacy of cetuximab.
H. Kohrt (2014)
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
P. van der Bruggen (1991)
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
X. Fan (2014)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
Can induction chemotherapy improve dysphagia in locally advanced esophageal/GEJ cancer?
Elizabeth Won (2014)
Neoantigens in cancer immunotherapy
T. Schumacher (2015)
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
L. Derré (2010)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
F. S. Hodi (2008)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
T. Powles (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
D. Zamarin (2014)
Current clinical trials testing combinations of immunotherapy and radiation.
M. Crittenden (2015)
Nivolumab in previously untreated melanoma without BRAF mutation.
C. Robert (2015)
LAG-3, a novel lymphocyte activation gene closely related to CD4
F. Triebel (1990)
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Chad Tang (2014)
This paper is referenced by
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma
Abhishek D Garg (2017)
SELF-AMPLIFYING RNA VECTORS ENCODING SURVIVIN AS ANTI-TUMORAL VACCINE CANDIDATES Relatore: Prof. Diego Maria Michele FORNASARI Correlatore: Prof. Antonio SICCARDI Coordinatore del Dottorato: Prof. Massimo LOCATI
Degli Studi (2016)
Local delivery of checkpoints antibodies
C. Wang (2017)
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression.
G. Koelwyn (2015)
C3d regulates immune checkpoint blockade and enhances antitumor immunity.
J. Platt (2017)
CTLA-4 Antibodies in Cancer Immunotherapy
Veerendra Koppolu (2016)
Oncolytic viruses armed with immunostimulatory genes for cancer treatment
Mantas Šilanskas (2018)
More efficient use of HER targeting agents in cancer therapy
Tiia Honkanen (2019)
A generic cell surface ligand system for studying cell#_#x2013;cell recognition
M. Eleanor (2019)
Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes
K. D. Alsibai (2018)
Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
H. Jiang (2019)
Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy
C. Perrinjaquet (2019)
A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models.
B. Ling (2017)
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
M. Ayers (2020)
Immune checkpoint inhibitors and endocrine side effects, a narrative review
L. Agrawal (2019)
Global HIV/AIDS Burden and Associated Diseases
C. K. Williams (2019)
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju Yeon Lee (2016)
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.
W. He (2017)
Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy
G. Chen (2020)
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Katelyn T. Byrne (2016)
Two cases of anti‐programmed cell death 1‐associated bullous pemphigoid‐like disease and eruptive keratoacanthomas featuring combined histopathology
J. P. Bandino (2017)
A Graphene-Based Glycan Biosensor for Electrochemical Label-Free Detection of a Tumor-Associated Antibody
Filip Kveton (2019)
Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists.
L. Peverelli (2020)
Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
Zhuoya Wan (2019)
Melanoma and immunotherapy bridge 2015
V. G. Y. Nanda (2016)
Tumor microenvironment as the “regulator” and “target” for gene therapy
J. Wu (2019)
Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
N. H. Goradel (2019)
Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment.
Huizhong Xiong (2019)
Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications.
Janna Krueger (2019)
Pt(IV) hybrids containing a TDO inhibitor serve as potential anticancer immunomodulators.
Shixian Hua (2019)
Time to abandon single-site irradiation for inducing abscopal effects
E. Brooks (2018)
Immunodeficient Mice: The Backbone of Patient-Derived Tumor Xenograft Models
D. Hirenallur-Shanthappa (2017)See more